ABIO ARCA biopharma Inc.

0.52
+0.02  (+4%)
Previous Close 0.5
Open 0.52
Price To Book 0.96
Market Cap 7240510
Shares 13,924,058
Volume 47,666
Short Ratio
Av. Daily Volume 568,572

SEC filingsSee all SEC filings

  1. 8-K - Current report 181184607
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181183697
  3. 8-K - Current report 181128484
  4. 8-K - Current report 181113827
  5. DEF 14A - Other definitive proxy statements 181079503

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released February 26, 2018 - no benefit shown in overall population. Received "no agreement" letter from FDA regarding SPA. Intends to meet FDA December 2018 regarding letter.
Gencaro - GENETIC-AF trial
Chronic Heart Failure

SEC Filings

  1. 8-K - Current report 181184607
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181183697
  3. 8-K - Current report 181128484
  4. 8-K - Current report 181113827
  5. DEF 14A - Other definitive proxy statements 181079503
  6. 8-K - Current report 181075798
  7. PRE 14A - Other preliminary proxy statements 181063410
  8. 8-K - Current report 181005498
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 181005264
  10. 8-K - Current report 18981290